Aspen Aerogels, Inc. ASPN 深 滬
等待開盤 09-09 09:30:00 美东时间
6.76
+0.150
+2.27%
華盛通- 最 高6.84
- 今 開6.63
- 成交量 190.82万股
- 最 低 6.51
- 昨 收 6.61
- 總市值 5.55亿
- 52周最高 30.24
- 市盈率 靜 40.58
- 換手率 2.32%
- 52周最低 4.16
- 委 比 66.32%
- 總股本 8217.44万
- 歷史最高 65.986
- 量 比 1.47
- 振 幅 4.99%
- 歷史最低 1.60
- 每 手 1
- 風險率 6.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aspen Aerogels’ Strategic Moves Amid Market Challenges
Aspen Aerogels Inc (($ASPN)) has held its Q2 earnings call. Read on for the mai...
08-13 08:22
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Canaccord Genuity Maintains Buy on Aspen Aerogels, Lowers Price Target to $10
Canaccord Genuity analyst George Gianarikas maintains Aspen Aerogels (NYSE:ASPN) with a Buy and lowers the price target from $11 to $10.
08-09 05:03
Examining the Future: Arq's Earnings Outlook
Arq (NASDAQ:ARQ) is gearing up to announce its quarterly earnings on Monday, 20...
08-09 03:04
Aspen Aerogels Reports Q2 2025 Financial Results
The latest announcement is out from Aspen Aerogels ( ($ASPN) ). Aspen Aerogels ...
08-07 18:58
Aspen Aerogels Q2 Adj. EPS $(0.04) Beats $(0.09) Estimate, Sales $78.02M Beat $72.53M Estimate
Aspen Aerogels (NYSE:ASPN) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 53.49 percent. This is a 119.05 percent decrease over earnings of $0.21 per share from the
08-07 18:31
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Aspen Aerogels to Participate in August Investor Conferences
Aspen Aerogels, Inc. announced its participation in two investor events in August: the Oppenheimer 28th Annual Technology, Internet & Communications Conference on August 11, 2025 (virtual), and the Canaccord Genuity 45th Annual Growth Conference on August 12-13, 2025 (Boston, MA). Key executives, including CFO Ricardo C. Rodriguez and Senior Director Neal Baranosky, will host one-on-one meetings and present key updates. Presentation materials wil...
07-31 20:30
Lexicon Pharmaceuticals To Present New Data On Diabetic Nerve Pain Burden At ASPN 2025 Conference
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be
07-18 20:02
Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL
Ascentage Pharma's Bcl-2 selective inhibitor lisaftoclax (APG-2575) has received conditional approval from China's NMPA for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including BTK inhibitors. This makes lisaftoclax the first Bcl-2 inhibitor approved in China and the second globally for CLL/SLL. The approval is based on a pivotal Phase ...
07-10 13:30
